Plasticity of fibroblasts demonstrated by tissue-specific and function-related proteome profiling

Clinical Proteomics

Volumn 11, Issue 1, 2014, Pages

  Slany, Astrid ^a   Meshcheryakova, Anastasia ^b,c   Beer, Agnes ^b,c   Ankersmit, Hendrik Jan ^c   Paulitschke, Verena ^d   Gerner, Christopher ^a,b,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Fibroblasts; Inflammatory activation; Primary human cells; Proteome profiling; Tumor stroma interactions

Indexed keywords

CELL PROTEIN; CHEMOKINE; GRO ALPHA PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLOD 2 PROTEIN; PROTEOME; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; BONE MARROW FIBROBLAST; CELL DIFFERENTIATION; CELL ISOLATION; CELL PLASTICITY; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LIQUID CHROMATOGRAPH; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG FIBROBLAST; MELANOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; SKIN FIBROBLAST; TANDEM MASS SPECTROMETRY; UPREGULATION;

EID: 84935893393     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-11-41     Document Type: Article

References (73)

1. Flavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD: Fibroblasts as novel therapeutic targets in chronic inflammation. Br J Pharmacol 2008,153(Suppl 1):S241-S246.
2. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M: Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001, 22:199-204. 10.1016/S1471-4906(01)01863-4
3. Naylor AJ, Filer A, Buckley CD: The role of stromal cells in the persistence of chronic inflammation. Clin Exp Immunol 2013, 171:30-35. 10.1111/j.1365-2249.2012.04634.x
4. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Can 2006, 6:392-401. 10.1038/nrc1877
5. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmouliere A, Varga J, De Wever O, Mareel M, Gabbiani G: Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012, 180:1340-1355. 10.1016/j.ajpath.2012.02.004
6. Marsh T, Pietras K, McAllister SS: Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta 1832, 2013:1070-1078.
7. Bissell MJ, Hines WC: Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011, 17:320-329. 10.1038/nm.2328
8. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013
9. De Wever O, Demetter P, Mareel M, Bracke M: Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008, 123:2229-2238. 10.1002/ijc.23925
10. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L: Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 2013, 34:2041-2051. 10.1007/s13277-013-0842-8
11. Sugimoto H, Mundel TM, Kieran MW, Kalluri R: Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006, 5:1640-1646. 10.4161/cbt.5.12.3354
12. Pilling D, Fan T, Huang D, Kaul B, Gomer RH: Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PloS one 2009, 4:e7475. 10.1371/journal.pone.0007475
13. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY: Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genetics 2006, 2:e119. 10.1371/journal.pgen.0020119
14. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO: Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 2002, 99:12877-12882. 10.1073/pnas.162488599
15. Postlethwaite AE, Shigemitsu H, Kanangat S: Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004, 16:733-738. 10.1097/01.bor.0000139310.77347.9c
16. Paulitschke V, Gruber S, Hofstatter E, Haudek-Prinz V, Klepeisz P, Schicher N, Jonak C, Petzelbauer P, Pehamberger H, Gerner C, Kunstfeld R: Proteome analysis identified the PPARgamma ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction. PloS one 2012, 7:e46103. 10.1371/journal.pone.0046103
17. Slany A, Haudek-Prinz V, Meshcheryakova A, Bileck A, Lamm W, Zielinski C, Gerner C, Drach J: Extracellular Matrix Remodeling by Bone Marrow Fibroblast-like Cells Correlates with Disease Progression in Multiple Myeloma. J Proteome Res 2014, 13:844-854. 10.1021/pr400881p
18. Slany A, Haudek-Prinz V, Zwickl H, Stattner S, Grasl-Kraupp B, Gerner C: Myofibroblasts are important contributors to human hepatocellular carcinoma: Evidence for tumor promotion by proteome profiling. Electrophoresis 2013, 34:3315-3325. 10.1002/elps.201300326
19. Rothlein R, Mainolfi EA, Kishimoto TK: Treatment of inflammation with anti-ICAM-1. Res Immunol 1993, 144:735-739. discussion 754-762 10.1016/S0923-2494(93)80058-7
20. De Boeck A, Hendrix A, Maynard D, Van Bockstal M, Daniels A, Pauwels P, Gespach C, Bracke M, De Wever O: Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics 2013, 13:379-388. 10.1002/pmic.201200179
21. Slany A, Paulitschke V, Haudek-Prinz V, Meshcheryakova A, Gerner C: Determination of cell type-specific proteome signatures of primary human leukocytes, endothelial cells, keratinocytes, hepatocytes, fibroblasts and melanocytes by comparative proteome profiling. Electrophoresis 2014, 35:1428-1438. 10.1002/elps.201300581
22. Salza R, Peysselon F, Chautard E, Faye C, Moschcovich L, Weiss T, Perrin-Cocon L, Lotteau V, Kessler E, Ricard-Blum S: Extended interaction network of procollagen C-proteinase enhancer-1 in the extracellular matrix. Biochem J 2014, 457:137-149. 10.1042/BJ20130295
23. Kato A, Okamoto O, Ishikawa K, Sumiyoshi H, Matsuo N, Yoshioka H, Nomizu M, Shimada T, Fujiwara S: Dermatopontin interacts with fibronectin, promotes fibronectin fibril formation, and enhances cell adhesion. J Biol Chem 2011, 286:14861-14869. 10.1074/jbc.M110.179762
24. Denk AE, Braig S, Schubert T, Bosserhoff AK: Slit3 inhibits activator protein 1-mediated migration of malignant melanoma cells. Int J Mol Med 2011, 28:721-726.
25. Bedekovics J, Kiss A, Beke L, Karolyi K, Mehes G: Platelet derived growth factor receptor-beta (PDGFRbeta) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis. Virchows Arch 2013, 463:57-65. 10.1007/s00428-013-1434-0
26. Donovan J, Shiwen X, Norman J, Abraham D: Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis Tissue Repair 2013, 6:10. 10.1186/1755-1536-6-10
27. Halfon S, Abramov N, Grinblat B, Ginis I: Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev 2011, 20:53-66. 10.1089/scd.2010.0040
28. Hida Y, Hamada J: Differential expressions of matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs and their endogenous inhibitors among histologic subtypes of lung cancers. Anticancer Agents Med Chem 2012, 12:744-752. 10.2174/187152012802650156
29. Denkers IA, Beelen RH, Ossenkoppele GJ, De Jong-de Boer AJ, Langenhuijsen MM: Differences of cellular composition and adhesion molecule expression in "leukemic" as compared with "normal" human long-term bone marrow cultures. Ann Hematol 1992, 64:210-216. 10.1007/BF01738298
30. Novince CM, Koh AJ, Michalski MN, Marchesan JT, Wang J, Jung Y, Berry JE, Eber MR, Rosol TJ, Taichman RS, McCauley LK: Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells. Am J Pathol 2011, 179:2431-2442. 10.1016/j.ajpath.2011.07.032
31. Novince CM, Michalski MN, Koh AJ, Sinder BP, Entezami P, Eber MR, Pettway GJ, Rosol TJ, Wronski TJ, Kozloff KM, McCauley LK: Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism. J Bone Miner Res 2012, 27:11-25. 10.1002/jbmr.508
32. Bae S, Park CW, Son HK, Ju HK, Paik D, Jeon CJ, Koh GY, Kim J, Kim H: Fibroblast activation protein alpha identifies mesenchymal stromal cells from human bone marrow. Br J Haematol 2008, 142:827-830. 10.1111/j.1365-2141.2008.07241.x
33. Hu Q, Guo C, Li Y, Aronow BJ, Zhang J: LMO7 mediates cell-specific activation of the Rho-myocardin-related transcription factor-serum response factor pathway and plays an important role in breast cancer cell migration. Mol Cell Biol 2011, 31:3223-3240. 10.1128/MCB.01365-10
34. Nakatani K, Okuyama H, Shimahara Y, Saeki S, Kim DH, Nakajima Y, Seki S, Kawada N, Yoshizato K: Cytoglobin/STAP, its unique localization in splanchnic fibroblast-like cells and function in organ fibrogenesis. Lab Invest 2004, 84:91-101. 10.1038/labinvest.3700013
35. Yan C, Ding X, Wu L, Yu M, Qu P, Du H: Stat3 downstream gene product chitinase 3-like 1 is a potential biomarker of inflammation-induced lung cancer in multiple mouse lung tumor models and humans. PloS one 2013, 8:e61984. 10.1371/journal.pone.0061984
36. Bell SM, Schreiner CM, Wert SE, Mucenski ML, Scott WJ, Whitsett JA: R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis. Development 2008, 135:1049-1058. 10.1242/dev.013359
37. Foronjy R, Imai K, Shiomi T, Mercer B, Sklepkiewicz P, Thankachen J, Bodine P, D'Armiento J: The divergent roles of secreted frizzled related protein-1 (SFRP1) in lung morphogenesis and emphysema. Am J Pathol 2010, 177:598-607. 10.2353/ajpath.2010.090803
38. Groffen AJ, Buskens CA, Van Kuppevelt TH, Veerkamp JH, Monnens LA, van den Heuvel LP: Primary structure and high expression of human agrin in basement membranes of adult lung and kidney. Eur J Biochem 1998, 254:123-128. 10.1046/j.1432-1327.1998.2540123.x
39. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427. 10.1172/JCI0214276
40. Gallagher PE, Cook K, Soto-Pantoja D, Menon J, Tallant EA: Angiotensin peptides and lung cancer. Curr Cancer Drug Targets 2011, 11:394-404. 10.2174/156800911795538048
41. Liao W, Bao Z, Cheng C, Mok YK, Wong WS: Dendritic cell-derived interferon-gamma-induced protein mediates tumor necrosis factor-alpha stimulation of human lung fibroblasts. Proteomics 2008, 8:2640-2650. 10.1002/pmic.200700954
42. Brinckmann J, Kim S, Wu J, Reinhardt DP, Batmunkh C, Metzen E, Notbohm H, Bank RA, Krieg T, Hunzelmann N: Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol 2005, 24:459-468. 10.1016/j.matbio.2005.07.002
43. Wu J, Reinhardt DP, Batmunkh C, Lindenmaier W, Far RK, Notbohm H, Hunzelmann N, Brinckmann J: Functional diversity of lysyl hydroxylase 2 in collagen synthesis of human dermal fibroblasts. Exp Cell Res 2006, 312:3485-3494. 10.1016/j.yexcr.2006.07.013
44. Bock O, Hoftmann J, Theophile K, Hussein K, Wiese B, Schlue J, Kreipe H: Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol 2008, 172:951-960. 10.2353/ajpath.2008.071030
45. Brentnall TA: Arousal of cancer-associated stromal fibroblasts: palladin-activated fibroblasts promote tumor invasion. Cell Adh Migr 2012, 6:488-494. 10.4161/cam.21453
46. Ronty MJ, Leivonen SK, Hinz B, Rachlin A, Otey CA, Kahari VM, Carpen OM: Isoform-specific regulation of the actin-organizing protein palladin during TGF-beta1-induced myofibroblast differentiation. J Invest Dermatol 2006, 126:2387-2396. 10.1038/sj.jid.5700427
47. Xin H, Pereira-Smith OM, Choubey D: Role of IFI 16 in cellular senescence of human fibroblasts. Oncogene 2004, 23:6209-6217. 10.1038/sj.onc.1207836
48. Li T, Diner BA, Chen J, Cristea IM: Acetylation modulates cellular distribution and DNA sensing ability of interferon-inducible protein IFI16. Proc Natl Acad Sci U S A 2012, 109:10558-10563. 10.1073/pnas.1203447109
49. Sponza S, De Andrea M, Mondini M, Gugliesi F, Gariglio M, Landolfo S: Role of the interferon-inducible IFI16 gene in the induction of ICAM-1 by TNF-alpha. Cell Immunol 2009, 257:55-60. 10.1016/j.cellimm.2009.02.007
50. Anisowicz A, Messineo M, Lee SW, Sager R: An NF-kappa B-like transcription factor mediates IL-1/TNF-alpha induction of gro in human fibroblasts. J Immunol 1991, 147:520-527.
51. Brach MA, Henschler R, Mertelsmann RH, Herrmann F: Regulation of M-CSF expression by M-CSF: role of protein kinase C and transcription factor NF kappa B. Pathobiology 1991, 59:284-288. 10.1159/000163664
52. van de Stolpe A, Caldenhoven E, Stade BG, Koenderman L, Raaijmakers JA, Johnson JP, van der Saag PT: 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 1994, 269:6185-6192.
53. Basile A, Sica A, D'Aniello E, Breviario F, Garrido G, Castellano M, Mantovani A, Introna M: Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem 1997, 272:8172-8178. 10.1074/jbc.272.13.8172
54. Bocian C, Urbanowitz AK, Owens RT, Iozzo RV, Gotte M, Seidler DG: Decorin potentiates interferon-gamma activity in a model of allergic inflammation. J Biol Chem 2013, 288:12699-12711. 10.1074/jbc.M112.419366
55. Hayashi N, Yoshimoto T, Izuhara K, Matsui K, Tanaka T, Nakanishi K: T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-gamma and IL-13 production. Proc Natl Acad Sci U S A 2007, 104:14765-14770. 10.1073/pnas.0706378104
56. Nikolaou K, Sarris M, Talianidis I: Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer. Clin Cancer Res 2013, 19:2810-2816. 10.1158/1078-0432.CCR-12-1961
57. Bozoky B, Savchenko A, Csermely P, Korcsmaros T, Dul Z, Ponten F, Szekely L, Klein G: Novel signatures of cancer-associated fibroblasts. Int J Cancer 2013, 133:286-293. 10.1002/ijc.28035
58. Noda T, Yamamoto H, Takemasa I, Yamada D, Uemura M, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H: PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver Int 2012, 32:110-118. 10.1111/j.1478-3231.2011.02619.x
59. Norman J: Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim Biophys Acta 2011, 1812:1327-1336. 10.1016/j.bbadis.2011.06.012
60. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blattler WA, Chittenden T, Singh R: An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003, 63:5073-5083.
61. Bergman D, Halje M, Nordin M, Engstrom W: Insulin-like growth factor 2 in development and disease: a mini-review. Gerontology 2013, 59:240-249. 10.1159/000343995
62. Greenall SA, Bentley JD, Pearce LA, Scoble JA, Sparrow LG, Bartone NA, Xiao X, Baxter RC, Cosgrove LJ, Adams TE: Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer. J Biol Chem 2013, 288:59-68. 10.1074/jbc.M112.432013
63. Breuhahn K, Schirmacher P: Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol 2008, 14:1690-1698. 10.3748/wjg.14.1690
64. Jelinek DF, Witzig TE, Arendt BK: A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 1997, 159:487-496.
65. Barron DA, Rowley DR: The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 2012, 19:R187-R204. 10.1530/ERC-12-0085
66. Gundacker NC, Haudek VJ, Wimmer H, Slany A, Griss J, Bochkov V, Zielinski C, Wagner O, Stockl J, Gerner C: Cytoplasmic proteome and secretome profiles of differently stimulated human dendritic cells. J Proteome Res 2009, 8:2799-2811. 10.1021/pr8011039
67. Mortz E, Krogh TN, Vorum H, Gorg A: Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis. Proteomics 2001, 1:1359-1363.
68. Slany A, Haudek VJ, Gundacker NC, Griss J, Mohr T, Wimmer H, Eisenbauer M, Elbling L, Gerner C: Introducing a new parameter for quality control of proteome profiles: consideration of commonly expressed proteins. Electrophoresis 2009, 30:1306-1328. 10.1002/elps.200800440
69. Nesvizhskii AI, Keller A, Kolker E, Aebersold R: A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003, 75:4646-4658. 10.1021/ac0341261
70. Griss J, Gerner C: GPDE: a biological view on PRIDE. J Proteomics Bioinform 2009, 2:167-174. 10.4172/jpb.1000074
71. Griss J, Haudek-Prinz V, Gerner C: GPDE: A biological proteomic database for biomarker discovery and evaluation. Proteomics 2011, 11:1000-1004. 10.1002/pmic.201000507
72. Wimmer H, Gundacker NC, Griss J, Haudek VJ, Stattner S, Mohr T, Zwickl H, Paulitschke V, Baron DM, Trittner W, Kubicek M, Bayer E, Slany A, Gerner C: Introducing the CPL/MUW proteome database: interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells. Electrophoresis 2009, 30:2076-2089. 10.1002/elps.200900072
73. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, Mann M: Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 2005, 4:1265-1272. 10.1074/mcp.M500061-MCP200